[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Hospital of China Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":612},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,50,73,102,126,148,173,200,228,248,270,296,316,340,363,384,405,425,446,471,494,520,543,565,590],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100630106","phase-2-conversion-therapy-with-folfox-haic-plus-lenvatinib-and-tislelizumab-for-hepatocellular-carcinoma-with-vp3-portal-vein-tumor-thrombus-100630106",false,"NCT07483359","Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus","Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib and Tislelizumab for Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus: A Prospective, Multicenter, Single-arm Study","CONV3RSION","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be enrolled in this trial:\n\n1. Voluntarily sign the written informed consent form.\n2. Age 18 to 80 years (inclusive), male or female.\n3. Histologically or cytologically confirmed Hepatocellular Carcinoma (HCC) according to the \"Clinical Practice Guideline for Primary Liver Cancer (2024 Edition),\" and evaluated by a Multi-Disciplinary Team (MDT) as initially unresectable.\n4. No prior systemic anti-tumor therapy (including targeted therapy, immunotherapy, and systemic chemotherapy).\n5. Barcelona Clinic Liver Cancer (BCLC) stage C and China Liver Cancer (CNLC) stage IIIa, complicated with imaging-confirmed Vp3 portal vein tumor thrombus (PVTT, defined as tumor thrombus invading the first-order branches of the portal vein but not the main trunk).\n6. At least one measurable target lesion according to RECIST v1.1 criteria.\n7. Expected survival time of ≥ 3 months.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n9. Child-Pugh liver function class A or B (score ≤ 7).\n10. Adequate major organ function, meeting the following baseline laboratory criteria:\n\n    * Hematology: Hemoglobin ≥ 90 g\u002FL; Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\\^9\u002FL; Platelet count ≥ 75 x 10\\^9\u002FL.\n    * Biochemistry: Albumin ≥ 28 g\u002FL; Total Bilirubin ≤ 3 x Upper Limit of Normal (ULN); AST and ALT ≤ 5 x ULN; Alkaline Phosphatase (ALP) ≤ 5 x ULN; Serum Creatinine ≤ 1.5 x ULN.\n    * Coagulation: INR or Prothrombin Time (PT) ≤ 1.5 x ULN; Activated Partial Thromboplastin Time (APTT) ≤ 1.5 x ULN.\n11. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to enrollment, must not be breastfeeding, and must agree to use highly effective contraception during the study treatment and for at least 6 months after the last dose.\n12. Good compliance and willingness to cooperate with all study-related follow-up procedures.\n13. Assessed by the MDT as \"Potentially Resectable\" according to the \"Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition)\". This is defined as participants who are temporarily unsuitable for upfront surgical resection due to oncological factors (e.g., Vp3 PVTT indicating a high risk of early post-operative recurrence) or technical factors (e.g., massive tumor size leading to insufficient future liver remnant \\[FLR\\]), but who are expected to convert to an R0 resection and achieve significant clinical benefit following downstaging with the combination of FOLFOX-HAIC and systemic therapy.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from the study:\n\n1. History of other active malignancies within 5 years (except for adequately treated basal cell carcinoma of the skin or papillary thyroid cancer).\n2. Evidence of extrahepatic metastasis confirmed by chest, abdomen, and pelvis CT and\u002For MRI scans.\n3. Presence of clinically significant ascites.\n4. History of hepatic encephalopathy.\n5. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on chest CT scan at screening.\n6. Severe infection within 4 weeks prior to enrollment, including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia.\n7. History of hypertensive crisis; or major cardiovascular disease within 3 months prior to starting study treatment (e.g., New York Heart Association \\[NYHA\\] Class II or worse heart failure, myocardial infarction, cerebrovascular accident, unstable arrhythmia, or unstable angina).\n8. Inadequately controlled arterial hypertension, defined as systolic blood pressure (BP) ≥ 150 mmHg and\u002For diastolic BP \\> 100 mmHg (based on an average of ≥ 3 BP readings obtained from ≥ 2 measurements). Achieving these parameters through the use of antihypertensive therapy is permitted.\n9. Severe vascular disease within 6 months (e.g., aortic aneurysm requiring surgical repair or peripheral arterial thrombosis); or a current or recent history of active autoimmune disease or immunodeficiency (including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis).\n10. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the investigational drugs, may affect the interpretation of the results, or may place the patient at high risk for treatment-related complications.\n11. Use of systemic immunosuppressive medications within 2 weeks prior to the first dose of study treatment, or the expected need for long-term systemic immunosuppressive therapy during the study. Exceptions permitting the use of corticosteroids include: (1) prophylactic use to prevent allergic reactions to imaging contrast media (e.g., short-term dexamethasone); (2) topical, ophthalmic, intra-articular, otic, or inhaled corticosteroids with minimal systemic absorption; (3) physiological replacement doses of systemic corticosteroids (defined as ≤ 10 mg\u002Fday of prednisone or an equivalent corticosteroid).\n12. Evidence of bleeding diathesis or severe coagulopathy.\n13. Patients preparing to undergo, or who have previously received, a solid organ or allogeneic bone marrow transplant.","ALL","18 Years","80 Years",{"count":22,"type":23},38,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","Patients with hepatocellular carcinoma (HCC) complicated by Vp3 portal vein tumor thrombus (PVTT) face a poor prognosis and are typically ineligible for surgical resection. This prospective study evaluates a conversion therapy regimen-utilizing a combination of FOLFOX-HAIC, Lenvatinib, and Tislelizumab-designed to induce significant regression of both the tumor burden and the PVTT. The primary objective is to determine the Technical Resectability Rate (TRR), assessing the potential for this triple-combination therapy to downstage initially unresectable disease to a state suitable for curative-intent R0 surgical resection.",[29,30],"Hepatocellular Carcinoma (HCC)","Portal Vein Tumor Thrombus",[32,33,34,35,36],"Conversion Therapy","Hepatic Arterial Infusion Chemotherapy","Tislelizumab","Lenvatinib","Vp3 Portal Vein Tumor Thrombus","RECRUITING","2026-05-25",{"date":40,"type":41},"2026-05-28","ACTUAL",{"date":43,"type":41},"2026-05-20",{"date":45,"type":23},"2028-05",{"name":47,"class":48},"First Hospital of China Medical University","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":49},"100637423","first-in-human-study-of-the-radioligand-68ga--dota-epha2-100637423","NCT07593209","First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2","Development and Evaluation of 68Ga-DOTA-EphA2: A Novel Imaging Agent Targeting EphA2 for Malignant Tumor","EphA2","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Patients with suspected or histologically confirmed malignant tumors At least one measurable lesion identified by conventional imaging (CT, MRI, or ultrasound)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Ability to understand the study procedures and provide written informed consent\n* Adequate organ function allowing PET\u002FCT examination\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Severe hepatic, renal, cardiovascular, or pulmonary dysfunction considered --unsuitable for PET\u002FCT imaging\n* Known allergy or hypersensitivity to study-related compounds\n* Patients unable to tolerate PET\u002FCT examination or remain still during image acquisition\n* Participation in other investigational drug or radionuclide studies within 4 weeks prior to enrollment\n* Any medical or psychiatric condition judged by the investigators to interfere with study participation or interpretation of imaging results",{"count":59,"type":23},30,"OBSERVATIONAL","Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.",[63],"Malignant Tumor",[56],"2026-05-12",{"date":67,"type":41},"2026-05-18",{"date":69,"type":41},"2026-05-01",{"date":71,"type":23},"2027-12-31",{"name":47,"class":48},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":49},"100619889","llm-comanage-large-language-model-enabled-co-management-of-hypertension-diabetes-and-dyslipidemia-100619889","NCT07350486","LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia","A Cluster-Randomized Trial of Large Language Model-Enabled Coordinated Management for Hypertension, Diabetes, and Dyslipidemia in Community Settings (LLM-CoManage Trial)","LLM-CoManage","Inclusion Criteria:\n\nParticipating communities must meet all of the following criteria:\n\n* Have a designated community physician responsible for primary care who is capable of using a smartphone with stable internet access for clinical communication and LLM-assisted management;\n* No plan for administrative merger or restructuring within the next three years;\n* Located at least 2 kilometers away from adjacent participating communities (to minimize contamination between clusters).\n\nEligible participants must fulfill all of the following conditions:\n\n* Aged 40 years or older;\n* Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg;\n* Coexisting diabetes (HbA1c ≥ 7.0%) or coexisting dyslipidemia (LDL-C ≥ 3.4 mmol\u002FL\\[130 mg\u002FdL\\]);\n* Able to use a smartphone independently or with assistance from family members;\n* Has resided in the participating community for at least 6 months;\n* Has no plan to relocate in the next 3 years;\n* Enrolled in basic medical insurance for urban and rural residents, employee medical insurance, or the New Rural Cooperative Medical Scheme;\n* Not currently pregnant or planning pregnancy during the study period;\n* Free from malignant tumors and deemed to have a life expectancy of at least 3 years, as judged by study physicians;\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:No specific exclusion criteria.","40 Years",{"count":83,"type":23},6800,[85],"NA","This study aims to evaluate the effectiveness of a large language model (LLM)-supported, community-based integrated management model in improving cardiometabolic multimorbidity control among adults with hypertension and coexisting diabetes or dyslipidemia. Adopting an interventional study design, eligible patients will be recruited to compare the disease control indicators between LLM-assisted management and conventional management, so as to verify the effectiveness and safety of the former.",[88,89,90],"Hypertension","Diabetes","Dyslipidemia",[92,93],"Large Language Model","Co-Management","NOT_YET_RECRUITING","2026-05-09",{"date":97,"type":41},"2026-05-13",{"date":99,"type":23},"2026-06-15",{"date":71,"type":23},{"name":47,"class":48},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100636412","local-hyperthermia-combined-with-topical-3-hydrogen-peroxide-for-refractory-viral-warts-100636412","NCT07565350","Local Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts","Randomized Single-blind Parallel Controlled Clinical Trial of Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts","Inclusion Criteria:\n\n\\- 1: Patients with a disease course of ≥2 years who have failed to respond to ≥2 treatment methods (such as topical ointments, cryotherapy, laser therapy, etc.)\n\n2: The subject or their legal guardian is able to understand and sign the informed consent form\u002Fagree to participate in the study.\n\nExclusion Criteria:\n\n* 1: The subject or their legal guardian is unable to understand and refuses to sign the informed consent form \u002F refuses to participate in the study\n\n  2: Individuals allergic to local hyperthermia or hydrogen peroxide;\n\n  3: Subjects with tumors or other serious diseases are unable to complete this clinical study;\n\n  4: Due to personal or other objective reasons, it is not possible to ensure timely treatment and follow-up.",{"count":110,"type":23},80,[85],"1. Background of the Problem Viral warts result from infection of the skin or mucous membranes by human papillomavirus (HPV). Some patients develop refractory cases due to abnormal immune function, persistent viral presence, or recurrent warts. The clinical challenge in treating refractory viral warts lies in the limited effectiveness of single therapeutic approaches, high recurrence rates, and the fact that a significant proportion of patients are infected with high-risk or special HPV subtypes. These factors necessitate combined multi-modal treatments and genetic etiological screening.\n2. Current Treatment Status Thermotherapy (44°C ± 2°C, 30 minutes per session): Studies have demonstrated that it can stimulate the activation of local immune cells (such as Langerhans cells), thereby enhancing antiviral immune responses.\n\n   Hydrogen peroxide: It possesses antibacterial properties and promotes tissue repair. In keratinocytes, it can induce thermally induced pyroptosis, thereby enhancing the efficacy of antiviral treatment.\n3. HPV genotyping Refractory viral warts are often associated with infection by specific high-risk or low-risk HPV subtypes (e.g., HPV 16, 18, 2, 4, etc.). HPV genotype is closely linked to treatment outcomes and recurrence rates.\n4. Relevant pathogenic gene screening This involves exploring intrinsic patient susceptibility, such as genetic polymorphisms related to immune function (e.g., HLA typing or Toll-like receptor-related genes). It also includes screening for rare gene mutations, such as mutations in the GATA2, IL2RG, and DOCK8 genes, which lead to impaired viral clearance and a propensity to develop multiple viral warts.",[114],"Refactory Warts",[116],"Thermotherapy; Hydrogen peroxide; Refractory viral warts","2026-04-26",{"date":119,"type":41},"2026-05-04",{"date":121,"type":41},"2025-10-01",{"date":123,"type":23},"2027-12-30",{"name":47,"class":48},2,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":18,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":24,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":49},"100634067","hyperthermia-combined-with-hydrogen-peroxide-microneedle-patch-for-viral-warts-100634067","NCT07534865","Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts","A Randomized, Parallel-Group, Controlled, Assessor-Blinded Clinical Trial of Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts","Inclusion Criteria:\n\n1. Age 6-65 years, male or female;\n2. Clinically diagnosed with common warts, palmar\u002Fplantar\u002Fdigital warts (≥1 lesion), with a Physician's Wart Assessment score ≥2 (0: no visible wart, no further treatment required; 1: visible wart, diameter \\\u003C3 mm; 2: single wart diameter ≥3 mm and \\\u003C6 mm; 3: single wart diameter ≥6 mm);\n3. The subject or legal guardian is able to understand and sign the informed consent form and agrees to participate in the study.\n\nExclusion Criteria:\n\n1. Subjects presenting with atypical warts clinically;\n2. Subjects with immune dysfunction or autoimmune diseases;\n3. Pregnant or breastfeeding women;\n4. Subjects who have received human papillomavirus (HPV) vaccination within the past 6 months;\n5. Subjects who have undergone the following systemic treatments within the specified time frames: immunomodulators\u002Fimmunosuppressants (e.g., etanercept), within 4 months; corticosteroids (inhaled and intranasal use permitted), within 1 month;\n6. Subjects who have received the following treatments on or around the warts within the specified time frames: laser or other photochemical therapies (intense pulsed light, photodynamic therapy), within 3 months; immunotherapy (candida antigen), within 4 months; cryotherapy with liquid nitrogen, within 2 months; hydrogen peroxide, within 3 months; antimetabolite therapy (5-fluorouracil), within 2 months; retinoids, within 3 months;\n7. Subjects with a history of the following diseases prior to enrollment: skin malignancy within the past 6 months, premalignant skin conditions (actinic keratosis) within the past 6 months, or currently in the acute progressive phase of skin or systemic diseases (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.) or presenting with conditions (such as sunburn, open wounds) that may increase the risk of participation or interfere with evaluation;\n8. Subjects with diseases affecting skin healing, such as diabetes mellitus, vitamin A deficiency, etc.;\n9. Subjects with cold-sensitive conditions such as cryoglobulinemia or cold urticaria that may lead to abnormal observation results;\n10. Subjects with severe dysfunction of the heart, lung, liver, kidney, hematopoietic system, or other vital organs.","6 Years","65 Years",{"count":136,"type":23},210,[85],"Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc. Significant progress has been made in the application of hyperthermia for viral skin diseases. Clinically, the addition of hydrogen peroxide solution can enhance the efficacy of hyperthermia in treating HPV infection. As a common transdermal drug delivery method, microneedles can increase drug penetration and thereby further improve treatment outcomes. Based on these findings, this study aims to explore an adjunctive approach to hyperthermia for treating viral warts to further enhance therapeutic efficacy.\n\nThis study employs a randomized, parallel-group, assessor-blinded design. Participants will be randomly assigned to three groups: hyperthermia alone, hyperthermia combined with microneedle patch (loaded with 0.9% saline), and hyperthermia combined with hydrogen peroxide microneedle patch (experimental group). An adaptive design will be adopted. The sample size is estimated at 70 participants per group, accounting for a potential 20% dropout rate. Interim analyses will be conducted during follow-up, and enrollment will be stopped when a positive result is reached for the primary efficacy endpoint (cure rate), at which point the sample size will be adjusted accordingly.",[140],"Warts","2026-04-10",{"date":143,"type":41},"2026-04-16",{"date":69,"type":23},{"date":146,"type":23},"2028-12-01",{"name":47,"class":48},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":24,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":49},"100631666","phase-4-clinical-observation-of-xeligekimab-in-the-treatment-of-moderate-to-severe-palmoplantar-pustulosis-100631666","NCT07503652","Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis","Inclusion Criteria:Age: 18 - 75 years old, gender not restricted. Clinically diagnosed PPP for at least 6 months, meeting the diagnostic criteria of Navarini et al. (2017, Br J Dermatol).\n\nModerate to severe PPP: Baseline PPPASI score ≥ 12, PPPIGA score ≥ 3 (moderate or severe).\n\nDermatology Life Quality Index (DLQI) score ≥ 10. Has received at least one local or systemic treatment (such as high-dose corticosteroids, methotrexate) in the past and the treatment was ineffective or intolerable.\n\nThe patient or the patient's family signs the informed consent form. -\n\nExclusion Criteria:oInclude other types of psoriasis (such as pustular, erythrodermic, or punctate).\n\nHave used IL-17A inhibitors within the recent 3 months, or IL-23\u002FTNF-α inhibitors within the past 4 months.\n\nHave severe comorbidities (such as ALT\u002FAST \\> 3 times the upper limit of normal, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n\nActive infections (tuberculosis, hepatitis B, hepatitis C, HIV), pregnancy or lactation, drug allergies, participation in other clinical studies, etc.\n\n\\-","75 Years",{"count":156,"type":23},10,[158],"PHASE4","Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of life of patients. Currently, the treatment options for PPP are limited. Traditional therapies such as topical glucocorticoids, phototherapy and oral immunosuppressants have unsatisfactory efficacy, and long-term use may cause significant side effects. The introduction of biologics has provided a new direction for the treatment of PPP, but targeted therapy research for PPP is still scarce, and there are unmet clinical needs. The exploratory study of Xeligekimab in PPP is expected to provide a new treatment option, alleviate symptoms and improve the quality of life of patients. This study takes the domestic Xeligekimab as the research object, aiming to verify its potential in PPP and contribute to the breakthrough of domestic biologics in the field of refractory skin diseases. If the study is successful, it can provide preliminary evidence support for the addition of PPP as an indication for Xeligekimab and offer a preliminary theoretical basis for adding a new option to targeted therapy for PPP.",[161],"Palmoplantar Pustulosis (PPP)",[163,164],"Xeligekimab","Palmoplantar pustulosis","2026-03-25",{"date":167,"type":41},"2026-03-31",{"date":169,"type":23},"2026-03",{"date":171,"type":23},"2027-12",{"name":47,"class":48},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":59},"100629609","phase-3-precision-reperfusion-therapy-for-disabling-minor-stroke-with-large-vessel-occlusion-beyond-time-window-100629609","NCT07476898","Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase Versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke With Large Vessel Occlusion Beyond 4.5 Hours (TIME-MINOR Trial)","TIME-MINOR","Inclusion Criteria:\n\n* Male or female subjects (age ≥ 18 years).\n* Diagnosis of acute ischemic stroke, with intracranial hemorrhage ruled out by CT or MRI.\n* Time from stroke onset or last known well to randomization is 4.5 to 24 hours.\n* NIHSS score 2-5 and meeting the definition of disabling deficit: complete hemianopia (NIHSS question 3 score ≥ 2); severe aphasia (NIHSS question 9 score ≥ 2); neglect (NIHSS question 11 score ≥ 1); any persistent limb weakness against gravity (NIHSS question 6 or 7 score ≥ 2); any functional deficit considered potentially disabling by the physician and patient, such as inability to perform basic activities of daily living (bathing, independent walking, toileting, personal hygiene, and eating) or return to work.\n* LVO (internal carotid artery, middle cerebral artery M1\u002FM2 segments) confirmed by CTA or MRA, including tandem lesions.\n* Core infarct volume \\\u003C 70 ml, ischemic penumbra volume ≥ 15 ml, and mismatch ratio ≥ 1.8, as shown by CTP or MRI+MRP.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Significant pre-stroke neurological deficit (pre-stroke mRS ≥ 2).\n* History of stroke within the last 3 months.\n* History of intracranial hemorrhage.\n* Suspected subarachnoid hemorrhage.\n* Intracranial tumor, vascular malformation, or aneurysm.\n* Major surgery within the last 1 month.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg.\n* Platelet count \\\u003C 10⁵\u002Fmm³.\n* Heparin or oral anticoagulant therapy within 48 hours.\n* Abnormal APTT.\n* Thrombin or factor Xa inhibitors.\n* Severe illness with life expectancy \\\u003C 3 months.\n* Blood glucose \\\u003C 50 mg\u002FdL (2.7 mmol\u002FL).\n* Participation in any other investigational drug or device study within the last 3 months.\n* Pregnancy.\n* Patients deemed unsuitable for the registry study by the investigator.",{"count":182,"type":23},864,[184],"PHASE3","To verify the efficacy and safety of intravenous tenecteplase (TNK) in patients with disabling minor stroke and large vessel occlusion (LVO) within a 4.5-24 hour time window.",[187],"Stroke",[189,190,191],"Ischemic Stroke with Large Vessel Occlusion","Tenecteplase","beyond 4.5 hours","2026-03-12",{"date":194,"type":41},"2026-03-17",{"date":196,"type":23},"2026-03-01",{"date":198,"type":23},"2028-08-01",{"name":47,"class":48},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":18,"minAge":19,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":227},"100617472","left-ventricular-myocardial-work-for-predicting-response-to-crt-100617472","NCT07319065","Left Ventricular Myocardial Work for Predicting Response to CRT","Left Ventricular Myocardial Work for Predicting Response to Cardiac Resynchronization Therapy (CRT): A Multi-Center Study","CARE-MW","Healthy Adults Group\n\nInclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled:\n\n  1. Of Han Chinese ethnicity\n  2. Aged 18-79 years\n  3. Normal blood pressure (\\\u003C 140\u002F90 mmHg)\n  4. Normal fasting blood glucose\n  5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)\n  6. Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)\n  7. Normal liver and renal function (alanine transaminase \\\u003C 2× upper limit of normal; normal creatinine and blood urea nitrogen)\n  8. Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)\n  9. No structural heart disease and normal cardiac function confirmed by echocardiography\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Clinically significant cardiac valve regurgitation (≥ mild severity)\n2. Respiratory diseases: acute or chronic respiratory disorders\n3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.\n4. Abnormal liver function (alanine transaminase \\> 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)\n5. Other systemic diseases: anemia, malignancy, connective tissue disease, large artery\u002Fperipheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.\n6. Pregnant or lactating women\n7. Professional athletes\n8. Poor-quality ultrasound images that cannot support parameter measurement and analysis\n\nHeart failure patients with LBBB who are scheduled for CRT treatment Group\n\nInclusion criteria:\n\n1. LVEF ≤ 35%\n2. QRS ≥ 150ms; LBBB\n3. At least 3 months of optimal drug therapy before implantation\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.\n\nPatients with LBBB who have preserved LVEF Group\n\nInclusion criteria:\n\n1. LVEF≥53%\n2. LBBB\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.\n\nPatients with reduced LVEF but without LBBB Group\n\nInclusion criteria:\n\n1. LVEF ≤ 35%\n2. non-LBBB\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.",true,"79 Years",{"count":211,"type":23},3240,"This study aims to establish the normal reference values for left ventricular myocardial work in healthy Chinese adults and the influencing factors. Non-invasive myocardial work serves as a new parameter for identifying CRT responders and provides a scoring system for predicting the efficacy of CRT in clinical practice. CRT can improve cardiac function and quality of life, and reduce mortality and hospitalization rates due to heart failure (HF). Currently, the number of CRT treatments is increasing year by year, but even when strictly following the indications, approximately 30% of patients do not respond. Therefore, precise prediction of CRT efficacy is of great clinical significance for improving prognosis. Currently, the indications for CRT mainly rely on clinical, electrocardiogram (CLBBB), and LVEF. By correcting ventricular contraction asynchrony to improve systolic function, however, CLBBB indicates electrical asynchrony, and LVEF improvement depends on mechanical synchrony. If the mechanical asynchrony of the ventricles can be evaluated directly before surgery, it will help predict the efficacy of CRT. Myocardial work is a recently developed non-invasive method that combines LV afterload with the overall longitudinal strain (GLS) analysis of echocardiography. Myocardial work reflects the contraction ability of the heart, stroke work, residual myocardial contraction ability, myocardial oxygen consumption, useless work, useful work, etc., and is represented by the pressure-volume loop analysis, thus having the potential to predict the efficacy of CRT. Therefore, this study intends to adopt the left ventricular myocardial work technique, combined with the current indication criteria, to predict the long-term efficacy of patients with heart failure who are scheduled for CRT treatment, thereby increasing the response rate of CRT and improving the prognosis of patients. Currently, there are no normal reference values for left ventricular myocardial work in healthy Chinese adults. Therefore, our center has initiated this multicenter clinical research project, collaborating with multiple ultrasound centers across the country, aiming to establish the normal ultrasound values for left ventricular myocardial work in healthy Chinese adults, providing new quantitative reference basis for the diagnosis of myocardial function, assessment of the severity of myocardial lesions, and efficacy observation.",[214,215,216,217],"CRT Non-Response","LBBB","HF - Heart Failure","Healthy Adult",[219],"Myocardial work","2025-12-21",{"date":222,"type":41},"2026-01-06",{"date":224,"type":23},"2026-01-01",{"date":71,"type":23},{"name":47,"class":48},82,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":208,"sex":18,"minAge":234,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":49},"100614993","digital-technology-combined-with-blood-marker-screening-and-diagnosis-for-community-populations-based-on-classification-theory-an-integrated-study-100614993","NCT07286812","Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study","Inclusion Criteria:\n\n1. Adults aged 50 and above;\n2. Residents of this community for at least one year, with established medical records;\n3. Deny a history of cognitive impairment diseases (mild cognitive impairment, dementia, Alzheimer's, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.);\n4. Agree to participate in the study;\n5. The individual and their relatives can communicate normally in Chinese.\n\nExclusion Criteria:\n\n1. Self-reported or confirmed through inquiry that there is a severe mental disorder, such as bipolar disorder or schizophrenia, etc.\n2. Suffering from a disease that makes it impossible to complete the cognitive assessment.","50 Years",{"count":236,"type":23},1000,"Our research hypothesis is as follows: A step - by - step screening strategy based on screening technologies can resolve the issue of insufficient efficiency in the traditional scale - based screening model. Meanwhile, performing pathological diagnoses on patients with suspected cognitive impairment identified through screening is conducive to the further implementation of etiology - based treatment and intervention, thus bringing benefits to patients at the earliest possible stage.\n\nBy exploring the characteristic changes in gait, facial expressions, and language of patients with suspected cognitive impairment and analyzing their diagnostic efficiency for cognitive impairment patients, new ideas can be provided for the early diagnosis of the disease.\n\nThrough longitudinal observation of the changes in disease - related information during the progression and transformation of the disease, a predictive model for the early diagnosis of cognitive impairment and the prediction of disease progression can be constructed.",[239],"Alzheimer Disease","2025-12-13",{"date":242,"type":41},"2025-12-16",{"date":244,"type":23},"2025-12-25",{"date":246,"type":23},"2026-07-31",{"name":47,"class":48},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":254,"minAge":19,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":24,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100616410","phase-2-clinical-study-of-shr-a1811-with-or-without-letrozole-in-neoadjuvant-therapy-for-early-stage-hr-positive-her2-low-breast-cancer-100616410","NCT07305246","Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer","Inclusion Criteria:\n\n1. Female, aged ≥18 years and ≤70 years;\n2. Histopathologically confirmed invasive breast cancer with no prior systemic anticancer therapy for breast cancer;\n3. Histopathologically confirmed HR-positive (ER ≥1% and\u002For PR ≥1%) with HER2-low expression (defined as IHC 1+\u002F2+ and FISH negative);\n4. Stage II-III breast cancer (cT2-cT4 or N+, cM0) according to the 8th edition AJCC Breast Cancer Staging Manual;\n5. At least one measurable target lesion per RECIST V1.1;\n6. ECOG performance status score of 0 to 1;\n7. Organ function levels must meet the following requirements (no corrective therapy with blood components or growth factors within 14 days prior to first dose):\n\n   1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL, platelets ≥100×10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL;\n   2. Hepatic and renal function: Albumin level ≥ 3.0 g\u002FdL, total bilirubin ≤ 1.5×upper limit of normal(ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×ULN, alkaline phosphatase ≤ 2.5×ULN, blood urea nitrogen and serum creatinine ≤ 1.5×ULN or creatinine clearance ≥60 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n   3. Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5×ULN;\n   4. Echocardiogram (ECHO) showing left ventricular ejection fraction (LVEF) ≥ 50%;\n   5. QTcF ≤ 470 msec;\n8. Pregnancy tests must be performed within 7 days prior to treatment initiation for premenopausal women of childbearing potential. Serum pregnancy tests must be negative, and participants must not be breastfeeding. All enrolled patients must use adequate barrier contraception throughout the treatment cycle and for 6 months post-treatment;\n9. Voluntary participation in the study, signed informed consent, good compliance, and willingness to attend follow-up visits and undergo study-related procedures.\n\nExclusion Criteria:\n\n1. Breast cancer not confirmed by histopathological examination;\n2. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer;\n3. Prior receipt of any form of antitumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);\n4. Concurrent administration of any other form of antitumor therapy;\n5. History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ;\n6. Participation in other drug clinical trials within 4 weeks prior to randomization;\n7. Administration of live or attenuated vaccines within 4 weeks prior to randomization;\n8. Undergone major non-breast cancer-related surgical procedures within 4 weeks prior to randomization, or not yet fully recovered from such procedures;\n9. Presence of any active autoimmune disease or history of autoimmune disease with potential for recurrence, including but not limited to: autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (subjects controllable solely with hormone replacement therapy may be included); subjects with skin conditions not requiring systemic treatment such as vitiligo, psoriasis, or alopecia; controlled type 1 diabetes managed with insulin therapy; or childhood asthma in complete remission requiring no intervention in adulthood may be included; subjects with asthma requiring medical intervention with bronchodilators;\n10. History of immunodeficiency disorders, including HIV-positive status, other acquired or congenital immunodeficiency diseases, or history of organ transplantation;\n11. Uncontrolled or significant cardiovascular or cerebrovascular disease, including (but not limited to): occurrence of any of the following within 6 months prior to first dosing: congestive heart failure (NYHA Class III or IV), myocardial infarction or cerebral infarction (excluding lacunar infarction), pulmonary embolism, unstable angina, or presence of treatable arrhythmia at screening; Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, or unclassified cardiomyopathy); History of clinically significant QTc prolongation, second-degree type II atrioventricular block or third-degree atrioventricular block, or QTc interval (F method) \\>470 msec (females); atrial fibrillation (EHRA classification ≥2b); uncontrolled hypertension deemed unsuitable for study participation by the investigator;\n12. Subjects with known or suspected interstitial pneumonia; other conditions within three months prior to first dosing that may interfere with interfering with drug-related pulmonary toxicity monitoring or management, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia\u002Fobstructive bronchiolitis, pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease (COPD), obstructive\u002Frestrictive lung disease, or any autoimmune, connective tissue, or inflammatory disease affecting the lungs, such as rheumatoid arthritis, Sjögren's syndrome, or sarcoidosis, or prior history of total lung replacement;\n13. Active hepatitis B (HBsAg positive and HBV DNA ≥ 500 IU\u002FmL), hepatitis C (HCV antibody positive and HCV RNA above upper limit of normal range), or cirrhosis; or severe infections requiring antibiotics, antivirals, or antifungals for control;\n14. Known hereditary or acquired bleeding or thrombotic tendencies (e.g., hemophilia, coagulation disorders, etc.);\n15. Known allergy or contraindication to the study drug or its excipients;\n16. Pregnant or lactating female patients; female patients of childbearing potential with a positive baseline pregnancy test; or female patients of childbearing potential unwilling to use effective contraception throughout the study period;\n17. Concomitant conditions judged by the investigator to pose a serious threat to patient safety or interfere with study completion (including but not limited to uncontrolled severe hypertension, severe diabetes, active infections, etc.);\n18. History of defined neurological or psychiatric disorders, including epilepsy or dementia, or any other condition deemed by the investigator to make the patient unsuitable for this study.","FEMALE","70 Years",{"count":257,"type":23},120,[26],"This is a prospective, randomized, multi-cohort, Phase II clinical trial. The study plans to enroll 120 patients with early-stage or locally advanced, HR-positive, HER2-low breast cancer. The primary objective is to evaluate the efficacy and safety of SHR-A1811 with or without endocrine therapy compared to standard chemotherapy as neoadjuvant treatment.\n\nEligible subjects will be randomized centrally via an Interactive Web Response System (IWRS) using a block randomization method. Participants will be assigned in a 1:1:1 ratio to one of three treatment cohorts:\n\nCohort A: SHR-A1811 plus endocrine therapy (letrozole ± ovarian function suppression \\[OFS\\]) Cohort B: SHR-A1811 monotherapy Cohort C: Standard chemotherapy (investigator's choice of A\u002FEC-T or TEC regimen)\n\nNeoadjuvant Treatment:\n\nSubjects in Cohorts A and B will receive 8 cycles of their assigned regimen. Subjects in Cohort C will receive standard chemotherapy as per the chosen protocol.\n\nTreatment will continue until completion of the regimen, occurrence of unacceptable toxicity, withdrawal of consent, or discontinuation at the investigator's discretion.\n\nAssessments:\n\nTumor imaging for efficacy evaluation will be performed every 2 cycles, with responses assessed according to RECIST v1.1 criteria. Subjects who complete neoadjuvant treatment and are deemed eligible for surgery will undergo surgical intervention within 4 weeks after treatment completion. Pathological response will be assessed from the surgical specimen. Both radiological and pathological evaluations will be based on the assessments conducted at the study site.\n\nAdjuvant Therapy:\n\nFollowing surgery, all subjects will receive standard adjuvant endocrine therapy as clinically indicated.",[261],"Breast Cancer","2025-12-12",{"date":264,"type":41},"2025-12-26",{"date":266,"type":23},"2025-12",{"date":268,"type":23},"2027-09",{"name":47,"class":48},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":208,"sex":18,"minAge":19,"maxAge":209,"enrollmentInfo":276,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":278,"conditions":279,"keywords":285,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":7},"100615460","a-multicenter-study-on-the-normal-reference-range-and-clinical-significance-of-the-right-atrioventricular-coupling-index-assessed-by-artificial-intelligence-based-three-dimensional-echocardiography-100615460","NCT07292896","A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography","Healthy Adults Group\n\nInclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled:\n\n  1. Of Han Chinese ethnicity\n  2. Aged 18-79 years\n  3. Normal blood pressure (\\\u003C 140\u002F90 mmHg)\n  4. Normal fasting blood glucose\n  5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)\n  6. Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)\n  7. Normal liver and renal function (alanine transaminase \\\u003C 2× upper limit of normal; normal creatinine and blood urea nitrogen)\n  8. Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)\n  9. No structural heart disease and normal cardiac function confirmed by echocardiography\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Clinically significant cardiac valve regurgitation (≥ mild severity)\n2. Respiratory diseases: acute or chronic respiratory disorders\n3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.\n4. Abnormal liver function (alanine transaminase \\> 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)\n5. Other systemic diseases: anemia, malignancy, connective tissue disease, large artery\u002Fperipheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.\n6. Pregnant or lactating women\n7. Professional athletes\n8. Poor-quality ultrasound images that cannot support parameter measurement and analysis\n\nPulmonary Hypertension Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Aged 18-79 years\n2. Confirmed diagnosis via right heart catheterization: mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg, in accordance with the 2022 ESC\u002FERS guidelines\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Unable to complete right heart catheterization or pressure-volume loop assessment\n2. Complicated with significant left heart disease (left ventricular ejection fraction \\[LVEF\\] \\\u003C 50%, significant mitral valve disease)\n3. Pericardial disease or arrhythmias (e.g., atrial fibrillation) that severely impair right heart function evaluation\n4. Poor-quality images that prevent accurate measurement of right atrial or right ventricular parameters\n5. Concurrent liver or renal disease\n6. Concurrent malignancy\n7. History of surgical procedures such as pulmonary endarterectomy or balloon pulmonary angioplasty\n\nHeart Failure Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Aged 18-79 years\n2. Meets the 2022 AHA\u002FACC\u002FHFSA diagnostic criteria for heart failure\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1.Complicated with significant valvular heart disease (e.g., severe mitral regurgitation, severe tricuspid regurgitation, etc.)\n\nTricuspid Regurgitation Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Moderate or severe primary or secondary tricuspid regurgitation confirmed by echocardiography\n2. Aged 18-79 years\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Pericardial disease or arrhythmias (persistent atrial fibrillation) that interfere with measurements\n2. Congenital heart disease or residual lesions after surgical correction\n\nAtrial Septal Defect Group\n\nInclusion Criteria:\n\nPatients must meet all of the following criteria to be enrolled:\n\n1. Secundum atrial septal defect confirmed by echocardiography or transesophageal echocardiography\n2. Patients who have not undergone closure or surgical correction, or stable patients with \\> 3 months postoperatively\n3. Aged 18-79 years\n\nExclusion Criteria:\n\n1.Complicated with other complex congenital heart diseases.",{"count":277,"type":23},2640,"This multicenter study aims to establish the normal reference range of the Right Atrioventricular Coupling Index (RACI) in healthy Chinese adults using AI-based 3DE technology. It will also analyze the correlation between RACI and physiological parameters such as age, gender, and body surface area. Additionally, the study will explore the variation characteristics of RACI in patients with pulmonary hypertension, heart failure, tricuspid regurgitation, and atrial septal defect, and evaluate the clinical value of RACI in disease diagnosis, differential diagnosis, and risk stratification.",[280,281,282,283,284],"Healthy Adults","Pulmonary Hypertension","Tricuspid Regurgitation","Heart Failure","Atrial Septal Defect",[286,287,288],"Right Atrioventricular Coupling Index","3D Echocardiography","AI-assisted Imaging","2025-12-06",{"date":291,"type":41},"2025-12-18",{"date":266,"type":23},{"date":294,"type":23},"2026-12",{"name":47,"class":48},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":254,"minAge":19,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":24,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100613853","phase-2-trend-02---a-phase-ii-exploratory-de-escalation-trial-of-neoadjuvant-sacituzumab-govitecan-plus-tislelizumab-sgi-in-early-triple-negative-breast-cancer-100613853","NCT07271992","TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG\u002FI) in Early Triple-negative Breast Cancer","TREND-02","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years; 2. Histologically confirmed stage II or III primary invasive TNBC TNBC defined as: immunohistochemistry (IHC) ER and PR \\\u003C1%; HER2-negative, IHC 0 or 1+, IHC 2+, ISH-; 3. ECOG performance status score 0-1; 4. Provision of an acceptable tumor sample prior to randomization; 5. Bone marrow hematopoietic and organ function must meet study requirements; Without growth factor support or blood transfusion, ANC ≥ 1.5 × 10⁹\u002FL, platelets ≥ 100 × 10⁹\u002FL, hemoglobin ≥ 9 g\u002FdL; Bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN; Creatinine ≤ 1.5 × ULN; Urinalysis showing proteinuria \\\u003C 2+ or 24-hour urine protein \\\u003C 1 g; Coagulation function must be normal, defined as: International Normalized Ratio (INR) and\u002For Prothrombin Time (PT) ≤ 1.5 × ULN and\u002For Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN. If anticoagulant therapy is ongoing, PT must remain within the therapeutic range for the anticoagulant used.\n\nSerum amylase ≤ 1.5×ULN and serum lipase ≤ 1.5×ULN.\n\nExclusion Criteria:\n\n* 1\\. Evidence of severe\u002Funcontrolled systemic disease, including active infections requiring intravenous therapy, severe chronic gastrointestinal disease associated with diarrhea, active bleeding disorders, severe cardiac or psychiatric disorders, or history of allogeneic organ transplantation; 2. History of other primary malignancies with known active disease within 3 years prior to randomization and low potential for recurrence (excluding adequately excised non-melanoma skin cancers and treated carcinoma in situ); 3. Active or documented history of autoimmune or inflammatory diseases; 4. Presence of distant metastases; 5. Active or uncontrolled hepatitis B or C infection, uncontrolled HIV infection, or active tuberculosis; 6. History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, any clinically active interstitial lung disease, or immune-related pneumonitis induced by immunotherapy; 7. Any prior or concurrent surgery, radiotherapy, or systemic anticancer therapy for TNBC; 8. Prior exposure to the following treatments: Immunosuppressive drug therapy within 14 days before the first study intervention Live attenuated vaccines within 30 days before the first study intervention",{"count":59,"type":23},[26],"Refining neoadjuvant chemoimmunotherapy and establishing predictive biomarkers remain pivotal challenges in early TNBC. Although SG\u002FI (sacituzumab govitecan\u002FPD-1 inhibitor) shows clinical promise, validation of responder identification tools is warranted. This phase II trial aims to identify a precision TNBC population suitable for de-escalated neoadjuvant therapy with sacituzumab govitecan plus tislelizumab, based on differential Trop-2 expression (±) and PD-L1 status (CPS \\>10% vs. \\\u003C10%). Primary endpoints include pCR rate and safety; exploratory biomarker analyses will assess mechanisms of response\u002Fresistance",[307],"TNBC, Triple Negative Breast Cancer","2025-11-26",{"date":310,"type":41},"2025-12-09",{"date":312,"type":23},"2025-12-15",{"date":314,"type":23},"2031-12-14",{"name":47,"class":48},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":208,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":323,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":325,"conditions":326,"keywords":331,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":339},"100603207","a-multi-center-study-on-artificial-intelligence-based-quantitative-evaluation-of-echocardiography-100603207","NCT07133516","A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography","MAIQUEE","Inclusion Criteria:\n\n1. Age ≥18 - 80 years;\n2. Types of diseases (8 in total, 200 cases each):\n\n   1. Normal heart\n   2. Coronary heart disease (with segmental thinning and abnormal movement)\n   3. Valve disease (valve stenosis or reflux)\n   4. Hypertensive heart disease\n   5. Atrial fibrillation\n   6. Heart failure\n   7. Dilated cardiomyopathy\n   8. Hypertrophic cardiomyopathy\n\nExclusion Criteria:\n\n1. Patients with congenital heart disease\n2. Patients with poor image quality",{"count":324,"type":23},1600,"This project aims to collaborate with multiple medical institutions to verify the accuracy, stability, and clinical application value of AI algorithms in echocardiographic quantitative measurement through multi-center clinical research. Specific objectives include:\n\n1. Compare the automatic measurement results of AI with the manual measurement data from physicians of different levels, and analyze the measurement deviation and consistency of AI in key parameters such as intracardiac diameter, volume, and function.\n2. Investigate whether AI-assisted measurement can significantly reduce echocardiogram analysis time and optimize clinical workflows. Through multi-center data validation, establish a standardized reference system for AI ultrasound measurement, promote the promotion and application of AI technology in medical institutions at all levels, and reduce diagnostic differences between different hospitals and physicians.\n3. Exploring the application of AI in special cases: Assessing the measurement stability of AI algorithms in complex cases (such as cardiomyopathy, valvular disease, coronary heart disease, etc.), and optimizing AI models to meet broader clinical needs.",[327,328,329,330],"Artificial Intelligence (AI)","Artificial Intelligence (AI) in Diagnosis","Cardiovascular Diseases (CVD)","Echocardiography",[327,328,329,330],"2025-08-18",{"date":334,"type":41},"2025-08-21",{"date":336,"type":41},"2025-07-22",{"date":246,"type":23},{"name":47,"class":48},37,{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":24,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":49},"100579718","multicenter-real-world-study-of-hyperthermia-in-warts-of-special-population-100579718","NCT06827938","Multicenter Real-World Study of Hyperthermia in Warts of Special Population","Multicenter Real-World Study of Hyperthermia in Skin\u002FMucosal HPV Infection of Special Population","Inclusion Criteria:\n\n1. Pregnant women with viral warts\n2. Diagnosis of AIDS with viral warts\n3. Autoimmune disease patients with viral warts\n4. Diabetic patients with viral warts\n5. Patients with viral warts who are currently being treated with immunosuppressants\n6. Children with viral warts\n7. The subject or legal guardian is able to understand and sign the informed consent\u002Fconsent to participate in the study\n\nExclusion Criteria:\n\n1. The subject suffers from tumor or other serious disease and cannot complete this clinical study\n2. Timely treatment and follow-up cannot be guaranteed due to personal or other objective reasons",{"count":348,"type":23},400,[85],"Hyperthermia refers to treating diseases with temperatures beyond normal body temperature (39-45℃), and moxibustion therapy of traditional Chinese medicine belongs to the category of hyperthermia. It has been reported at home and abroad that the local temperature of 44℃ can effectively mobilize the body's immunity and remove HPV infection lesions, such as condyloma acuminatum and verruca vulgaris. Our research group conducted randomized controlled experiments on patients with viral warts in the early clinical practice, and the cure rate of the hyperthermia group reached 45-55%, which was superior to the traditional method in the aspects of no trauma, low recurrence rate, easy to tolerate and so on. Our research group's preliminary research on hyperthermia of viral warts has been included in the British Medical Association's guidelines for viral warts therapy. The equipment our research group developed has been obtained the medical device registration certificate, and is in the process of national promotion. Hyperthermia is to mobilize systemic immunity through local warm heat, the preliminary clinical study of the research group shows that the therapeutic effect of hyperthermia is usually \"all or none\": \"all\" that is, after hyperthermia, all viral warts are removed, including non-treatment lesions;\"None\" means that some patients with viral warts do not respond to hyperthermia. Cellular immunity plays a very important role in the removal of warts. At present, some special clinical patients such as pregnant women, children, patients with autoimmune diseases, diabetes, immunosuppressants after organ transplantation and other patients with skin\u002Fmucosal HPV infection, their warts show more extensive proliferation or a longer and repeated course of disease, treatment resistance, etc. It has increased the difficulty of clinical treatment, and the specific mechanism is still unclear. Therefore, for these special populations, how to further enhance the therapeutic effect of hyperthermia is the top priority of current research.\n\nIn view of the above findings, this research group intends to study the efficacy and safety of hyperthermia in the treatment of viral warts in the special population (pregnant women, children, patients with autoimmune diseases, diabetes, and immunosuppressants after organ transplantation, etc.) in a multicenter real-world study of skin\u002Fmucosal HPV infection in the special population.",[140],[353,354],"warts","local hyperthermia","2025-08-09",{"date":357,"type":41},"2025-08-14",{"date":359,"type":41},"2024-07-10",{"date":361,"type":23},"2027-07-10",{"name":47,"class":48},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":24,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":383,"locationsCount":49},"100539153","antifungal-agents-and-infrared-thermotherapy-alone-or-in-combination-in-the-treatment-of-sporotrichosis-100539153","NCT06300138","Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis","A Randomized Controlled Clinical Trial of Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis","Inclusion Criteria:\n\n* The results of pathology and fungal culture were all patients with sporotrichosis.\n* Informed consent to the purpose and content of the study, and follow-up as required\n* The physical condition and self-condition can cooperate with the treatment.\n\nExclusion Criteria:\n\n* Subjects who are unable to maintain a relatively stable posture during treatment.\n* Those who are sensitive or allergic to this experimental drug.\n* Systemic antifungal or KI therapy within 12 months\n* Local antifungal therapy within 1 month.\n* Previous history of immunodeficiency virus (HIV) infection, or positive HIV antibody in screening period.",{"count":371,"type":23},150,[85],"Sporotrichosis is a chronic granulomatous mycosis caused by sporothrix complex. The course of sporotrichosis is always prolonged and even life-threatening, the treatment of this disease in an important scientific problem to be solved. The investigators previously found the predominance of subtype M2 macrophage which play an anti-inflammatory role in the lesions of sporotrichosis, the predominance of M2 macrophage may be responsible for the persistence of sporotrichosis; the investigators also found that local hyperthermia is effective in the treatment of sporotrichosis and hyperthermia treatment can activate the CRAC calcium channel in macrophages which triggers pro-inflammatory type M1 polarization and subsequent killing of sporothrix, however, the mechanism still calls for further investigation. The investigators hypothesize that hyperthermia leads to the activation of CRAC channels resulting in profound Ca2+ influx and Ca2+ upregulates NLRP3 inflammasome expression through inducing Nrf2 activation, then NLRP3 overexpression triggers M1 polarization and subsequent killing of sporothrix. Furthermore, the activation of Nrf2 upregulates STIM1 expression which forms a positive feedback for M1 type polarization of macrophages and further subsequent killing of sporothrix. The purpose of this project is to identify the hypothesis that hyperthermia could treat sporotrichosis by promoting pro-inflammatory type M1 polarization in macrophages, the mechanism by which hyperthermia could treat sporotrichosis is local hyperthermia could led to STIM1\u002FCRAC calcium channel activation mediated calcium ions\u002FNrf2\u002FNLRP3 induced M1 macrophages polarization and subsequent killing of sporothrix. The hypothesis will be identified at the cellular level, at the animal model level and at the clinical specimens level. The investigators believe that the project will guide the application of hyperthermia in the treatment of sporotrichosis and provide a new basis of theory and practice after the investigators achieving these goals.",[375],"Sporotrichosis",[375,354],"2025-08-08",{"date":379,"type":41},"2025-08-13",{"date":381,"type":41},"2024-03-15",{"date":294,"type":23},{"name":47,"class":48},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":49},"100599527","the-multi-center-study-of-comprehensive-atrial-fibrillation-regurgitation-and-recurrent-events-evaluation-100599527","NCT07085650","The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation","The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation by 3-dimensional Transoesophageal Echocardiography and Recurrent Events Evaluation","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Patients who came to the hospital with atrial fibrillation and intended to undergo ablation.\n\nExclusion Criteria:\n\n1. \\- History of left atrial or left atrial appendix thrombus, new cerebral infarction and myocardial infarction (\\\u003C 6 months);\n2. Congenital heart disease, valvular heart disease, dilated heart disease, hypertrophic cardiomyopathy, pacemaker implantation, artificial valve replacement;\n3. hyperthyroidism, severe liver and kidney insufficiency;\n4. Proposed cardiac pacemaker implantation;\n5. Previous history of catheter ablation;\n6. The quality of three-dimensional transesophageal images was insufficient and could not be analyzed;\n7. refuse to sign the informed consent.",{"count":392,"type":23},2000,"Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic and can lead to valve regurgitation and a poor prognosis. At present, atrial fibrillation ablation is one of the most effective means for the recurrence of atrial fibrillation in clinical practice, but the recurrence rate is high. Therefore, it is of great significance to find the predictors of relapse after atrial fibrillation ablation for clinical precision treatment. three-dimensional transesophageal ultrasound (3D-TEE) can comprehensively evaluate the valve regurgitation, flap ring changes, atrial or auricular thrombosis in patients with atrial fibrillation. It is also a necessary examination before atrial fibrillation ablation.\n\nTherefore, this study intends to combine 3D-TEE and three-dimensional transthoracic echocardiographic (3D-TTE) examination to evaluate the cardiac structure and function of patients. To comprehensively evaluate atrial fibrillation valve regurgitation and explore the predictors of recurrence after atrial fibrillation ablation.",[395,396,282],"Atrial Fibrillation (AF)","Mitral Regurgitation","2025-07-24",{"date":399,"type":41},"2025-07-25",{"date":401,"type":41},"2024-12-30",{"date":403,"type":23},"2026-09-30",{"name":47,"class":48},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":412,"targetDuration":413,"studyType":60,"phases":4,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":49},"100596042","a-clinical-follow-up-study-on-drug-therapy-for-graves-disease-patients-in-china-100596042","NCT07040306","A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China","A Prospective Clinical Follow-up Study of Drug Treatment in Patients With Graves' Disease","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Newly diagnosed GD and GD relapses.\n\nExclusion Criteria:\n\n1. Patients with active infiltrative exophthalmos in GD were excluded.\n2. Patients with other autoimmune diseases affecting thyroid function were excluded.\n3. Excluding patients with combined malignancies and other serious diseases.",{"count":236,"type":23},"30 Years","This study was a prospective follow-up study of newly diagnosed and relapsed Graves' disease patients in the Endocrinology Clinic of the First Affiliated Hospital of China Medical University. The following aspects will be studied: 1. Through the prospective follow-up study of GD patients, we will get the relapse rate and remission rate of GD patients treated with drugs, explore the risk factors of GD patients relapsing after drug treatment, and make GD relapse risk prediction software; 2. To compare the effects of high dose and low dose methimazole on the remission rate, liver side effects, leukopenia and other adverse drug reactions, and to summarize the incidence and risk factors of liver side effects, leukopenia and other adverse drug reactions caused by drug treatment; 3. To investigate the sensitivity and specificity of TRAb in the diagnosis of GD in China and its role in predicting recurrence; 4. After taking ATD, the serum alkaline phosphatase of GD patients will increase first and then decrease. This study will focus on analyzing the dynamic changes of this index before and after methimazole treatment, and analyze the relationship between it and thyroid function index.",[416],"Graves´ Disease","2025-07-03",{"date":419,"type":41},"2025-07-09",{"date":421,"type":41},"2012-11-14",{"date":423,"type":23},"2030-12-01",{"name":47,"class":48},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":432,"targetDuration":434,"studyType":60,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":49},"100569605","phase-iv-study-vunakizumab-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis-100569605","NCT06696417","Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","A Prospective, Single-arm, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Vunakizumab in Adults With Moderate-to-severe Plaque Psoriasis Who Have Not Previously Received Biologics","Inclusion Criteria:\n\n* Age ≥18 years old at the time of signing the informed consent, regardless of gender;\n* Moderate to severe plaque psoriasis was diagnosed;\n* Plan to receive vunakizumab therapy as assessed by the investigator;\n* The subject voluntarily signs informed consent before the start of any procedures related to the study, can communicate with the researcher smoothly, understands and is willing to strictly comply with the requirements of this clinical study protocol to complete the study; Patients voluntarily sign informed consent forms.\n\nExclusion Criteria:\n\n* Previous treatment with biological agents: including but not limited to anti-tumor necrosis factor-α (TNF-α), anti-IL-17, anti-IL-17 receptor, anti-IL-12 \u002FIL-23 or IL-23p19 antibody drugs;\n* Severe hypersensitivity to vunakizumab active ingredient or any excipients;\n* Patients with clinically important active diseases, such as active tuberculosis, active hepatitis, and active malignant tumors;\n* Fertile women (defined as all women with physical conditions necessary for pregnancy) and men who are pregnant or unwilling or unable to use highly effective birth control during the study period and within 20 weeks after last receiving the study drug;\n* Any other circumstances that the investigator believes will prevent the subject from following and completing the study protocol.",{"count":433,"type":23},1516,"60 Weeks","This is a multicenter, prospective, observational study of 1516 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of vunakizumab in patients with moderate-to-severe chronic plaque psoriasis. Approximately 50-100 clinical trial centers are planned to participate in the study. The study consisted of a 7-day screening period, a 52-week treatment period and an 8-week safety follow-up period.\n\nThe recommended dose of vunakizumab is 240 mg (120 mg in two injections), with subcutaneous injection at week 0, 2, and 4, followed by a dose every 4 weeks and a final injection at week 48 (the actual treatment regimen is based on the clinician's recommendation). After the corresponding assessment at 52 weeks, an 8-week safety follow-up period was entered until the end of the study.",[437],"Moderate to Severe Plaque Psoriasis","2025-05-12",{"date":440,"type":41},"2025-05-14",{"date":442,"type":41},"2025-02-17",{"date":444,"type":23},"2028-04",{"name":47,"class":48},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":234,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":4},"100582801","efficacy-and-safety-of-conventional-symptomatic-drugs-combined-with-lencanizumab-in-the-treatment-of-early-alzheimers-disease-a-multicenter-prospective-observational-study-100582801","NCT06868030","Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study","Inclusion Criteria:\n\n1. Patients aged 50 and 85 years old, male or female;\n2. The subjects had primary school education (education) or above, normal hearing, vision and pronunciation, native tongue is Chinese, and daily language is Mandarin, and were able to complete the information collection stipulated in the program.\n3. The AD diagnosis met the diagnostic criteria for dementia described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), using the 2011 NIA-AA AD diagnostic criteria. The MCI diagnosis met the MCI diagnostic criteria of Peterson in 2004;\n4. The presence of amyloid deposits was confirmed by biomarkers: imaging or cerebrospinal fluid biomarkers.\n5. Having cognitive decline, having one of the following conditions: (a) MMSE score of 20 or above; (b) CDR-GS score of 0.5 or 1;\n6. The combination group met the criteria for cainumab (according to cainumab instructions);\n7. Willing and able to complete all the requirements of the study (including MRI, neuropsychological assessment, clinical genotyping, etc.);\n8. Established caregivers or family members can objectively conduct CDR, quality of life scale, daily life performance scale and other clinical assessments;\n9. The patient and their family members were informed and signed the informed consent form.\n\nExclusion Criteria:\n\n1. There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal skull pressure hydrocephalus, etc.);\n2. There are other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n3. Presence of serious or unstable diseases, including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, neurological (except AD), psychiatric, immune, or hematological diseases and other diseases that the investigator believes may affect the results of the study analysis, or a life expectancy of \\\u003C24 months;\n4. History of schizophrenia, schiztive disorder, major depression or bipolar disorder, and history of major depression may be enrolled in the study if no episodes occurred or mitigated or controlled in the past year; risk of suicide; a history of alcoholism and \u002F or substance abuse or dependence in the past 2 years (according to the Diagnostic and Statistical Manual of Mental Disorders, Version 5th standard)\n5. Severe stroke sequelae (mRS\\> 3 or previous stroke history);\n6. Clinically significant systemic immune participants due to the sustained effects of immunosuppressive drugs;\n7. Failure to tolerate MRI tests or with MRI contraindications, including but not limited to: a pacemaker incompatible with MRI, eye, skin, MRI clips, artificial heart valve, ear implant, or external metal implant, or other clinical history or findings of which MRI may cause potential harm;\n8. Subjects with a history of allergy to any treatment component such as cincainizumab;\n9. Refusal to sign the informed consent form.","85 Years",{"count":257,"type":23},"According to the World Health Organization, China will become the \"oldest\" country in the world by 2050, with 35 percent of the elderly population. At present, in the Chinese population of 60 years old, there are about 15.07 million dementia patients (about 6.0%), about 9.83 million Alzheimer's disease (AD) patients (about 3.9%), and about 38.77 million mild cognitive impairment (Mild cognitive impairment, MCI) patients (about 15.5%). A sharp increase in older people with cognitive impairment will bring a heavy disease burden, and the social cost is almost the sum of cancer, heart disease and stroke.\n\nAD is an age-related neurodegenerative disorder characterized by a progressive decline in cognitive function and daily living capacity. The amyloid hypothesis of AD suggests that the deposition of A β is an early and inevitable event in AD pathogenesis. This hypothesis suggests that therapies that slow the deposition of A β plaques in the brain or increase the clearance of A β may slow the progression of the AD clinical syndrome. Most of the disease course of patients with cognitive impairment is more than 10 years long. How to diagnose and treat them in the early stage has become a key link to delay the progression of the disease and reduce the burden. The disease progression of AD is divided into three major stages: preclinical AD (Preclinical AD, Pre-AD), AD-derived mild cognitive impairment (Mild cognitive impairment due to AD, MCI-AD) and AD dementia (which can be subdivided into mild, moderate and severe AD). Among them, MCI-AD and mild AD are collectively known as early AD, which are the earliest clinical symptoms and the best window for identification and intervention. Studies show that about 43.4% of patients with MCI-AD will progress to AD dementia within 4 years, and 80% will progress within 6 years. If the disease advances to moderate or severe AD, patients will develop severe cognitive, functional impairment and behavioral symptoms, which interfere with social function and need help from daily living activities; severe or even complete loss of independence, requiring round-the-clock care. If early diagnosis and effective interventions in the early stages of the disease, it will help delay the disease into the moderate and severe stages, prolong the quality of life of patients, and greatly reduce the social burden of care and treatment.\n\nAt present, the treatment of AD is mainly symptomatic treatment, mainly including cholinesterase inhibitors and NMDA receptor antagonists. Phase-phase clinical trials show that luncinelizumab has a positive impact on cognitive function and pathological indicators in patients with early AD, delaying the early AD disease process by up to 27% relative to placebo treatment. Lencanizumab, a disease-modifying therapy for early AD, has been approved by FDA and NMPA in China. With the wide clinical application, the clinical efficacy and safety of lencanizumab combined with classical symptomatic therapy have attracted great attention. However, there are still few studies on the clinical characteristics, diagnosis and treatment patterns, efficacy and safety of the combination, and clinical outcomes of patients with early AD in the real world.\n\nBased on this, this study intends to conduct an 18-month multi-center prospective real-world observational cohort study exploring the clinical characteristics, diagnosis and treatment patterns, efficacy and safety of the combination, caregiver and family burden of real-world early AD patients (MCI-AD and mild AD).",[456,457],"Alzheimer's Disease","MCI-AD, Early Stage Alzheimer's Disease",[459,460,461,462],"Alzheimer disease","MCI-AD, early stage Alzheimer's disease","lencanizumab","treatment","2025-03-05",{"date":465,"type":41},"2025-03-10",{"date":467,"type":23},"2025-04-01",{"date":469,"type":23},"2026-12-31",{"name":47,"class":48},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":478,"maxAge":134,"enrollmentInfo":479,"targetDuration":4,"studyType":24,"phases":481,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":493,"locationsCount":125},"100578497","randomized-controlled-clinical-trial-of-hyperthermia-and-hydrogen-peroxide-3-in-the-treatment-of-cutaneous-warts-100578497","NCT06812065","Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts","Rrandomized Controlled Clinical Trial Named Mild Local Hyperthermia and Hydrogen Peroxide Treat Multiple Warts by Targeting a Single Lesion.","Inclusion criteria: The participants were between 16 and 65 years of age, had a clinical diagnosis of viral warts (including common warts, plantar warts, or condyloma acuminatum), and could understand and sign informed consent.\n\nExclusion criteria: presented with clinically atypical warts; had immunocompromised status or a history of HIV infection; received HPV vaccination within the past 6 months; used immunomodulators, immunosuppressants, or systemic corticosteroids within defined timeframes (4 months and 1 month, respectively); underwent local therapies (e.g., laser, cryotherapy, retinoids) on or near warts within protocol-specified intervals; had a history of cutaneous malignancies or current precancerous lesions; exhibited active dermatologic\u002Fsystemic diseases (e.g., psoriasis, eczema) or skin conditions (e.g., sunburn) potentially increasing study risks; or were deemed ineligible by investigators for other medical or logistical reasons.","16 Years",{"count":480,"type":23},300,[85],"Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc.\n\nHydrogen peroxide (H2O2) is a commonly used disinfectant for skin debridement. It has been reported that high concentration of H2O2 (45% H2O2) is effective in the treatment of warts vulgaris, however, high concentration of H2O2 will cause more local pain, itching and burning sensation. 3% hydrogen peroxide is commonly used as skin debridement disinfectant.\n\nThe purpose of the study is to evaluate the efficacy and safety of 44℃ hyperthermia combined with 3% hydrogen peroxide in treating verruca virus.",[140],[485,140,486],"hyperthermia","Hydrogen Peroxide","2025-02-02",{"date":489,"type":41},"2025-02-06",{"date":491,"type":41},"2022-12-07",{"date":469,"type":23},{"name":47,"class":48},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":154,"enrollmentInfo":501,"targetDuration":4,"studyType":24,"phases":503,"briefSummary":504,"conditions":505,"keywords":508,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":49},"100565056","clinical-research-on-the-treatment-model-of-ambulatory-surgery-for-colorectal-cancer-100565056","NCT06637215","Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer","Open, Parallel, Randomized Controlled, Non-inferior, Phase III Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer","Inclusion Criteria:\n\n1. Patients voluntarily joined this study and signed an informed consent form；\n2. Age: 18-75 years old；\n3. The patient should have a good general condition and no serious internal medicine comorbidities (ASA classification of the American Anesthesiology Association is Grade I\\~III)；\n4. Complete colonoscopy and colonoscopy biopsy, and the pathology is confirmed to be adenocarcinoma\u002Fhigh-level intraepithelial neoplasia；\n5. Enhanced CT or MRI examination before surgery, indicating that the tumor diameter is ≤5.0 cm；\n6. Preoperative staging: cT1-3NanyM0;\n7. Strictly follow the colorectal day surgery plan, and micro-laparoscopic radical colorectal cancer treatment can be adopted；\n8. There are no contraindications for abdominal wall nerve block anesthesia or non-opiate analgesic drugs;\n9. Does not require conventional anticoagulant therapy or antiplatelet therapy；\n10. Relatives or co-residents should be able to provide 24 hours of full escort within at least 72 hours after the operation, the place of residence is not more than a 30-minute drive from the hospital, and they can understand and follow the phased treatment plan of diet, analgesic drugs, etc. after the operation.\n\nExclusion Criteria:\n\n1. Elderly patients with multiple basic diseases；\n2. Moderate to severe anemia；\n3. Severe hypoproteinemia；\n4. Diabetes that is not well controlled；\n5. Contraindications to laparoscopic surgery；\n6. Cases of emergency surgery due to acute intestinal obstruction, perforation or bleeding；\n7. Patients with distant metastases；\n8. Patients who are unwilling to sign informed consent or follow-up according to the research plan；\n9. People with a history of psychotropic drug abuse and unable to quit or have mental disorders；\n10. Patients who live alone or in psychosocial isolation, patients who cannot understand the postoperative nursing process；\n11. After the operation, the place of residence is far away from the treated hospital or patients with insufficient medical resources and inconvenient transportation；\n12. According to the judgment of the researcher, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the patient\\'s research.",{"count":502,"type":23},352,[85],"To investigate the postoperative complication incidence and long-term efficacy between ambulatory surgery for colorectal cancer and traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions。",[506,507],"Colorectal Carcinoma","Day Surgery",[509,510,511],"Colorectal cancer","Day surgery","Laparoscope","2024-11-24",{"date":514,"type":41},"2024-11-27",{"date":516,"type":41},"2023-11-01",{"date":518,"type":23},"2029-03-31",{"name":47,"class":48},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":154,"enrollmentInfo":527,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":49},"100564662","haic-in-combination-with-pd-1-inhibitors-and-lenvatinib-for-intermediate-and-advanced-hcc-after-the-failure-of-systemic-therapy-recommended-by-bclc-100564662","NCT06632093","HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of portal vein tumor thrombus;\n3. Has received previous systemic therapy recommended for HCC by BCLC, and the systemic therapy failed;\n4. Both PD-1inhibitors and Lenvatinib patients received only include marketed drugs but are not limited to HCC approval;\n5. HAIC was performed after the first PD-1 inhibitor\u002F Lenvatinib treatment or before treatment;\n6. Received at least 2 cycles of HAIC；\n7. Has repeated measurable intrahepatic lesions;\n8. Child-Pugh class A or B.\n\nExclusion Criteria:\n\n1. The interval between the failure of systemic therapy and the beginning of combination therapy longer than 3 months;\n2. With other malignant tumors;\n3. Unable to meet criteria of combination timeframe described above.",{"count":528,"type":23},84,"The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.",[531,532,33,35,533,534],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","PD-1","Systemic Therapy","2024-10-06",{"date":537,"type":41},"2024-10-08",{"date":539,"type":41},"2024-09-16",{"date":541,"type":23},"2025-12-30",{"name":47,"class":48},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":18,"minAge":550,"maxAge":20,"enrollmentInfo":551,"targetDuration":4,"studyType":24,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":564,"locationsCount":4},"100555175","phase-4-effects-of-dl-3-n-butylphthalide-on-chemotherapy-induced-cognitive-impairment-100555175","NCT06508671","Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment","Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment (NBP CICI)：a Prospective, Randomized, Double Blinded, Multicenter, Placebo Controlled Study","Inclusion Criteria:\n\n1. Treatment with paclitaxel drugs (such as paclitaxel\u002Fdocetaxel\u002Falbumin-based paclitaxel, etc.) or platinum-based chemotherapy (cisplatin), and not combined with other chemotherapy drugs; (Cancer type is not limited)\n2. Sign the informed consent and understand the purpose and significance of the study;\n3. Aged between 35 and 80 years old;\n4. Ability to complete the questionnaire on their own or with assistance;\n5. Complaints of cognitive impairment involving memory and\u002For other cognitive areas lasting for at least 3 months;\n6. Cancer treatment has been completed and is considered curable, with the exception of endocrine therapy after chemotherapy;\n7. MMSE score: 18-26;\n8. Clinical Dementia Rating (CDR) score: 0.5-2;\n9. Fluent in Chinese;\n10. No visual or hearing impairment;\n11. Did not participate in another intervention study within 6 months prior to commencing this study;\n\nExclusion Criteria:\n\n1. Diagnosed with a cognitively impaired disease, such as Alzheimer's disease;\n2. Patients will be excluded from fMRI testing if they are claustrophobic, have MRI contraindications such as pacemakers or metal implants, and patients who did not undergo fMRI testing may still participate in clinical trials if all other enrollment criteria are met;\n3. Take medications that may affect cognitive function\n4. History of brain metastases or other brain tumors;\n5. History of stroke or severe head trauma;\n6. History of epilepsy or other seizures;\n7. Pregnant or considering becoming pregnant;\n8. Any active nervous system or untreated\u002Funremitted mental disorder (such as active major depressive disorder or other major mental disorder described in the DSM-5, allowing treatment of depression if treatment is stable)\n9. Any history of alcohol or drug abuse or dependence within the past 2 years;\n10. Any major systemic disease or unstable medical condition that may cause difficulty in complying with the protocol, including: a history of myocardial infarction or instability in the past year, serious cardiovascular disease (including angina or congestive heart failure with resting symptoms, or clinically significant abnormalities in the electrocardiogram), clinically significant and\u002For unstable lung, gastrointestinal, liver or kidney disease;\n11. Have taken any non-research drugs to improve cognitive function within 4 weeks prior to enrollment;\n12. Have taken butylphthalein in the past 30 days.","35 Years",{"count":552,"type":23},100,[158],"Chemotherapy-related cognitive Impairment (CICI) is a series of neurocognitive deficits experienced during and after cancer chemotherapy. Studies have reported that CICI affects 25% to 75% of survivors and can persist for years after chemotherapy is discontinued, causing more severe progressive manifestations and placing a heavy burden on families and society. Numerous studies have proposed several potential mechanisms and etiologies for CICI, including direct neurotoxicity, disruption of the blood-brain barrier, reduced hippocampal neurogenesis, white matter abnormalities, secondary neuroinflammatory responses, and increased oxidative stress. At present, there is no clear and effective diagnosis and therapy for CICI, and how to diagnose and treat cognitive impairment caused by chemotherapy effectively is still the focus and difficulty.\n\nBased on the previous consensus on the application of dl-3-n-butylphthalide, butylphthalein can play a neuroprotective role by reducing oxidative stress and inflammatory response, inhibiting neuronal apoptosis, improving mitochondrial function and other mechanisms, and significantly improve the performance of the central nervous system caused by cerebral ischemia and vascular dementia. However, the increase of neuroinflammatory response and oxidative stress is precisely one of the potential mechanisms of CICI pathogenesis. Therefore, based on the above findings, this study hypothesized that dl-3-n-butylphthalide would also have considerable efficacy in the treatment of CICI.",[556,557],"Chemotherapy-Related Cognitive Impairment","DL-3-n-butylphthalide","2024-07-14",{"date":560,"type":41},"2024-07-18",{"date":562,"type":23},"2024-07",{"date":294,"type":23},{"name":47,"class":48},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":254,"minAge":19,"maxAge":20,"enrollmentInfo":572,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":589},"100537820","early-prediction-and-warning-for-cardiotoxicity-due-to-anthracycline-based-breast-cancer-chemotherapy-100537820","NCT06282796","Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy","Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy\n* LVEF≥53% before chemotherapy\n\nExclusion Criteria:\n\n* life expectancy ≤12 months\n* Participating in other ongoing oncology clinical trials\n* Prior treatment with anthracyclines or chest radiation therapy\n* Pregnant or lactating women\n* Ultrasound images of the heart are of very poor quality",{"count":573,"type":23},600,"This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.",[261],[577,578,579,580],"Breast Cancer Chemotherapy","Anthracyclines","Cardiotoxicity","Early detection","2024-02-21",{"date":583,"type":41},"2024-02-28",{"date":585,"type":41},"2024-01-01",{"date":587,"type":23},"2028-12-31",{"name":47,"class":48},5,{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":208,"sex":18,"minAge":234,"maxAge":452,"enrollmentInfo":596,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":4},"100522357","multimodal-deep-learning-for-the-diagnosis-and-assessment-of-alzheimers-disease-100522357","NCT06081569","Multimodal Deep Learning for the Diagnosis and Assessment of Alzheimer's Disease","Inclusion Criteria:\n\n1. . Participants' age is between 50 and 85 years old, male or female;\n2. . Participants graduated from primary school or above, with normal hearing, vision, and pronunciation, using Chinese as their mother tongue and Mandarin as their daily language；\n3. . The diagnosis of AD and MCI participants conform to the corresponding diagnostic criteria mentioned above;\n4. . The scores of MMSE are between 10 and 28, and the scores of CDR are no more than 2.\n5. . Patients or family members agree to sign informed consent.\n\nExclusion Criteria:\n\n1. . Participants suffer from neurological disorders that could cause dysfunction of the brain, such as depression, tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal cranial pressure hydrocephalus, and so forth;\n2. . Participants suffer from systematic diseases that could cause cognitive impairment, such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, and so forth;\n3. . Participants suffer from diseases that are unable to cooperate with the examinations;\n4. . Participants cannot take magnetic resonance imaging;\n5. . Participants suffer from mental and neurodevelopmental retardation;\n6. . Participants refuse to sign informed consent.",{"count":480,"type":23},"Alzheimer's disease (AD) is the most common dementia and has been one of the most expensive diseases with the highest lethality. With the rapid increase of the aging population, more and more burdens will be posed on society and economics. The manifestations of AD are the progressive loss of memory, language and visuospatial function, executive and daily living abilities, and so forth. The Pathophysiological changes of AD occur 10-20 years before the clinical symptoms, while there is still a lack of effective strategy for early diagnosis. Mild cognitive impairment (MCI) is considered to be a transitional state between healthy aging and the clinical diagnosis of dementia and has received increasing attention as a separate diagnostic entity.\n\nTo make the diagnosis, doctors ought to compressively consider the multimodal medical information including clinical symptoms, neuroimages, neuropsychological tests, laboratory examinations, etc. Multimodal deep learning has risen to this challenge， which could integrate the various modalities of biological information and capture the relationships among them contributing to higher accuracy and efficiency. It has been widely applied in imaging, tumor pathology, genomics, etc. Recently, the studies on AD based on deep learning still mainly focused on multimodal neuroimaging, while multimodal medical information requires comprehensive integration and intellectual analysis. Moreover, studies reveal that some imperceptible symptoms in MCI and the early stage of AD may also play an effective role in diagnosis and assessment, such as gait disorder, facial expression identification dysfunction, and speech and language impairment. However, doctors could hardly detect the slight and complex changes, which could rely on the full mining of the video and audio information by multimodal deep learning.\n\nIn conclusion, we aim to explore the features of gait disorder, facial expression identification dysfunction, and speech and language impairment in MCI and AD, and analyze their diagnostic efficiency. We would identify the different degrees of dependency on multimodal medical information in diagnosis and finally build an optimal multimodal diagnostic method utilizing the most convenient and economical information. Besides, based on follow-up observations on the changes in multimodal medical information with the progress of AD and MCI, we expect to establish an effective and convenient diagnostic strategy.",[239,599],"Mild Cognitive Impairment",[601,602,459,599,603],"multimodal deep learning","diagnosis","assessment","2023-10-07",{"date":606,"type":41},"2023-10-13",{"date":608,"type":23},"2023-10-15",{"date":610,"type":23},"2026-10-15",{"name":47,"class":48},""]